Amgen said that an interim look at a Phase 2 trial of its anti-obesity drug MariTide had left the company “very encouraged,” and it planned to rapidly move forward with a final-stage program as well as boost manufacturing capacity for the experimental drug.
“We are confident in MariTide’s differentiated profile…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
